INDIANAPOLIS, -- Roche Diabetes Care, makers of ACCU-CHEK® products and services, is pleased to announce the availability of the new, user-friendly ACCU-CHEK Nano SmartView System. The ACCU-CHEK Nano meter, part of the ACCU-CHEK Nano SmartView System, offers enhanced features including: ease-of-use, fast and accurate readings and small, portable size. Moreover, the meter offers patients the flexibility to test at any time – day or night – with a brilliant backlit display.
"As a rock-climber, I was looking for a meter that fits into my active lifestyle and the ACCU-CHEK Nano meter does just that," said Steve Richert, rock-climber with type 1 diabetes, founder of the nonprofit organization, LivingVertical and spokesperson for Roche Diabetes Care's awareness campaign, Steve's Mountain. "The ACCU-CHEK Nano meter is simple for me to use and gives me accurate readings so I can ensure my insulin levels are under control before I start my climbs. Also, the display screen's visibility in the dark is a great feature because I'm often testing at night."
Diabetes affects 25.8 million children and adults in the United States; approximately 1 in 12 people. Regular and accurate monitoring of blood glucose levels through self-testing is essential to managing the disease and can reduce the risk of diabetes-related complications such as heart disease, stroke, kidney failure, nerve damage or blindness. An accurate blood glucose reading can help to inform a patient's food choice, insulin use and lifestyle habits.
The ACCU-CHEK Nano SmartView system offers advanced accuracy as tested against a 23% tighter specification – greater than the current standard set by the International Organization for Standardization (ISO) – so that people can manage their diabetes with confidence. (4) Testing with the meter only requires a small drop of blood (0.6 microliters) and provides a blood glucose reading within 5 seconds.
"We are pleased to offer an innovative, user-friendly blood glucose meter that can be easily integrated into the lives of people with diabetes," said Marc Gibeley, Head of Roche Diabetes Care North America. "It is a smaller, sleeker option in our broad portfolio of ACCU-CHEK meters. For more than 35 years, Roche Diabetes Care has been committed to the diabetes community, delivering best-in-class solutions that enable optimal diabetes management, and the ACCU-CHEK Nano meter builds upon that promise."
About the ACCU-CHEK Nano SmartView System
The ACCU-CHEK Nano blood glucose monitoring system features the ACCU-CHEK Nano meter, the ACCU-CHEK SmartView test strips and the ACCU-CHEK FastClix lancing device. The ACCU-CHEK Nano SmartView system offers a small, sleek design, no coding, a brilliant backlit display and advanced accuracy as tested against a 23% tighter specification. The ACCU-CHEK Nano meter, a part of the ACCU-CHEK Nano SmartView system, is available in pharmacies and retailers nationwide, as well as online anywhere ACCU-CHEK products are available.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: roche.com.
All trademarks used or mentioned in this release are protected by law.